Home Cart Sign in  
Chemical Structure| 1187075-34-8 Chemical Structure| 1187075-34-8

Structure of Resminostat HCl
CAS No.: 1187075-34-8

Chemical Structure| 1187075-34-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Resminostat HCl is a potent inhibitor of HDAC1/3/6 (IC50=43-72 nM) and less potent to HDAC8 with IC50 of 877 nM.

Synonyms: 4SC-201 hydrochloride; RAS2410 hydrochloride; RAS2410

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Resminostat HCl

CAS No. :1187075-34-8
Formula : C16H20ClN3O4S
M.W : 385.87
SMILES Code : O=C(NO)/C=C/C1=CN(S(=O)(C2=CC=C(CN(C)C)C=C2)=O)C=C1.[H]Cl
Synonyms :
4SC-201 hydrochloride; RAS2410 hydrochloride; RAS2410
MDL No. :MFCD26142920

Safety of Resminostat HCl

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Resminostat HCl

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
SeAx cells 5 µM 24 hours To evaluate the effects of Resminostat and Ruxolitinib on the proliferation and apoptosis of SeAx cells. Results showed that the combination significantly reduced cell viability (p < 0.001) and increased apoptosis (p < 0.001). Cancers (Basel). 2022 Feb 20;14(4):1070
MyLa cells 5 µM 24 hours To evaluate the effects of Resminostat and Ruxolitinib on the proliferation and apoptosis of MyLa cells. Results showed that the combination significantly reduced cell viability (p < 0.001) and increased apoptosis (p < 0.005). Cancers (Basel). 2022 Feb 20;14(4):1070
SeAx cells 10 µM 24 hours To evaluate the effect of Resminostat on the migration of SeAx cells. Results showed that Resminostat combined with Ruxolitinib significantly inhibited the transendothelial migration of SeAx cells (82% inhibition, p < 0.05). Cancers (Basel). 2024 Sep 17;16(18):3176
MyLa cells 10 µM 24 hours To evaluate the effect of Resminostat on the migration of MyLa cells. Results showed that Resminostat combined with Ruxolitinib significantly inhibited the transendothelial migration of MyLa cells (75% inhibition, p < 0.05). Cancers (Basel). 2024 Sep 17;16(18):3176
PC-3 cells 5 µM 24 hours RESM treatment significantly downregulated SIRT1 expression, enhancing VSVΔM51 infection and cancer cell killing J Virol. 2019 Jul 17;93(15):e00626-19
PC-3 cells 5 µM 24 hours RESM treatment upregulated CDKN1A gene expression while downregulating CDK6 and CCDN1 gene expression J Virol. 2019 Jul 17;93(15):e00626-19
PC-3 cells 5 µM 24 hours RESM treatment caused a reduction in S-phase cells and accumulation in G2/M phase, enhancing PC-3 cell sensitivity to VSVΔM51 infection J Virol. 2019 Jul 17;93(15):e00626-19
J-Lat 10.6 cells 2 µM 24 hours To evaluate the effect of resminostat alone or in combination with cGAMP on HIV latency reversal. Results showed that resminostat alone or in combination with cGAMP significantly increased the percentage of GFP-expressing cells, indicating HIV proviral reactivation. J Virol. 2019 Oct 15;93(21):e01194-19
SNU-387 0.02 to 50 µM 4 days To evaluate the anti-proliferative effects of Resminostat and Sorafenib in SNU-387 cells. Resminostat exhibited anti-proliferative activity in SNU-387 cells, independent of platelets. Sci Rep. 2021 May 5;11(1):9587
SNU-475 0.02 to 50 µM 4 days To evaluate the anti-proliferative effects of Resminostat and Sorafenib in SNU-475 cells. Resminostat exhibited anti-proliferative activity in SNU-475 cells, independent of platelets. Sci Rep. 2021 May 5;11(1):9587
HuH-7 0.02 to 50 µM 4 days To evaluate the anti-proliferative effects of Resminostat and Sorafenib in HuH-7 cells. Resminostat exhibited anti-proliferative activity in HuH-7 cells, independent of platelets. Sci Rep. 2021 May 5;11(1):9587
PLC/PRF/5 0.02 to 50 µM 4 days To evaluate the anti-proliferative effects of Resminostat and Sorafenib in PLC/PRF/5 cells. Resminostat exhibited anti-proliferative activity in PLC/PRF/5 cells, independent of platelets. Sci Rep. 2021 May 5;11(1):9587
HepG2 0.02 to 50 µM 4 days To evaluate the anti-proliferative effects of Resminostat and Sorafenib in HepG2 cells. Resminostat exhibited anti-proliferative activity in HepG2 cells, independent of platelets. Sci Rep. 2021 May 5;11(1):9587
ACH-2 cells 2 µM 48 hours To evaluate the effect of resminostat alone or in combination with cGAMP on HIV p24 expression in ACH-2 cells. Results showed that resminostat in combination with cGAMP significantly increased HIV p24 expression levels. J Virol. 2019 Oct 15;93(21):e01194-19
SW620 colon cancer cells 5 µM 72 hours To study the inhibitory effect of Resminostat on PD-L1 expression Int J Oncol. 2018 Oct;53(4):1469-1480
PLC/PRF/5 cells 1 µM 96 hours Evaluate the antitumor activity of Resminostat on PLC/PRF/5 cells, showing significant reduction in tumor cell mass in combination therapy. Mol Ther Oncolytics. 2015 Oct 7;2:15019
Hep3B cells 1 µM 96 hours Evaluate the antitumor activity of Resminostat on Hep3B cells, showing significant reduction in tumor cell mass in combination therapy. Mol Ther Oncolytics. 2015 Oct 7;2:15019
HepG2 cells 1 µM 96 hours Evaluate the antitumor activity of Resminostat on HepG2 cells, showing significant reduction in tumor cell mass in combination therapy. Mol Ther Oncolytics. 2015 Oct 7;2:15019

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chick embryo CTCL chick embryo model Topical administration 5 µM Every two days for 5 days To evaluate the effect of Resminostat combined with Ruxolitinib on angiogenesis in the CTCL chick embryo model. Results showed that the combination treatment significantly reduced blood vessel formation in MyLa and SeAx cells (49% and 34% reduction, respectively, p < 0.05). Cancers (Basel). 2024 Sep 17;16(18):3176
Chick embryo Chick embryo chorioallantoic membrane (CAM) model Topical administration 5 μM Resminostat and 15 μM Ruxolitinib Every two days for 7 days To evaluate the antitumor effects of Resminostat and Ruxolitinib in the CAM model of CTCL. Results showed that the combination significantly inhibited primary tumor size (p < 0.0001) and reduced liver and lung metastasis (p < 0.0001). Cancers (Basel). 2022 Feb 20;14(4):1070
SCID mice Orthotopic xenograft mouse model of Hep3B2.1-7 human liver cancer cells Oral Resminostat 15 mg/kg and 40 mg/kg, Sorafenib 40 mg/kg Daily administration for 21 days To evaluate the anti-tumor effects of Resminostat and Sorafenib alone and in combination in an orthotopic xenograft mouse model of liver cancer. Resminostat and Sorafenib alone significantly reduced tumor weight, and the combination further enhanced the anti-tumor effect. Sci Rep. 2021 May 5;11(1):9587

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.59mL

0.52mL

0.26mL

12.96mL

2.59mL

1.30mL

25.92mL

5.18mL

2.59mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories